Angelini Pharma has agreed to acquire Catalyst Pharmaceuticals in a deal valued at about $4.1 billion, according to multiple outlets. The transaction is set at $31.50 per share in cash, and the boards of directors of both companies have approved the acquisition unanimously. The offer represents a premium over Catalyst’s recent trading prices, with the premium reported as roughly 28% to 30% versus the 30-day volume-weighted average price as of April 22, 2026.
The companies describe the acquisition as expanding Angelini Pharma’s presence in the United States while strengthening its focus in areas including rare disease and brain health. Catalyst is known for its rare disease medicines, and the purchase is framed as consolidating Angelini’s leadership in those therapeutic areas.
Coverage from different outlets focuses on the same core terms: the $31.50 per-share cash consideration and the overall deal value of $4.1 billion, alongside the companies’ view that the combination will broaden Angelini’s market reach and therapeutic portfolio. Further steps and closing conditions are not detailed in the provided excerpts.
